Menlo's serlopitant meets endpoints in Phase II trial to treat prurigo nodularis patients

Pharmaceutical company Menlo Therapeutics' serlopitant has met the primary and secondary endpoints in the Phase II clinical trial (TCP-102) for the treatment of pruritus associated with prurigo nodularis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news